CN109350734A - Promote the composition and the preparation method and application thereof of nervous system reparation - Google Patents

Promote the composition and the preparation method and application thereof of nervous system reparation Download PDF

Info

Publication number
CN109350734A
CN109350734A CN201811000872.2A CN201811000872A CN109350734A CN 109350734 A CN109350734 A CN 109350734A CN 201811000872 A CN201811000872 A CN 201811000872A CN 109350734 A CN109350734 A CN 109350734A
Authority
CN
China
Prior art keywords
composition
nervous system
system reparation
promoting
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201811000872.2A
Other languages
Chinese (zh)
Inventor
陈建生
刘喜元
张慧
梁倩
李峰
胡欢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongbo Yuan Technology (shenzhen) Ltd Life
Original Assignee
Hongbo Yuan Technology (shenzhen) Ltd Life
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongbo Yuan Technology (shenzhen) Ltd Life filed Critical Hongbo Yuan Technology (shenzhen) Ltd Life
Priority to CN201811000872.2A priority Critical patent/CN109350734A/en
Publication of CN109350734A publication Critical patent/CN109350734A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/20—Aceraceae (Maple family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/69—Polygalaceae (Milkwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to pharmaceutical technology fields, provide a kind of composition and the preparation method and application thereof for promoting nervous system reparation.A kind of composition promoting nervous system reparation comprising nicotinamide adenine dinucleotide, ginsenoside PPD, ginseng saponin Rh 2, Herba Epimedii secondary aglycon, chondroitin sulfate, ursodesoxycholic acid, Sialic acid, s- Ademetionine, γ-aminobutyric acid, neurotrophic factor.The composition of the promotion nervous system reparation can play reparation to neuron and promote adjustment effect, and safe without toxic side effect.The present invention also provides the preparation method of the composition of the promotion nervous system reparation and applications.

Description

Promote the composition and the preparation method and application thereof of nervous system reparation
Technical field
The present invention relates to pharmaceutical technology field more particularly to a kind of composition for promoting nervous system reparation and its preparation sides Method and application.
Background technique
Nervous system includes central nervous system (brain, spinal cord) and peripheral neverous system (peripheral nerve tissue).Nerve System injury can be caused by many factors: (1) physical damnification directly contributes the neural tissue damage of damage location, as wound is made At cranial nerve tissue damage or spinal cord injury；(2) the temporarily or permanently ischemic or anoxic of partial nerve system, such as apoplexy or Cranial nerve tissue damage caused by cerebral embolism；(3) neurotoxin is contacted, such as the chemicals for the treatment of cancer or for treating The double deoxidation born of the same parents of AIDS are sweet；(4) chronic metabolic diseases, the peripheral nerve injury as caused by diabetes or renal dysfunction；(5) refreshing Through degenerative disease, including Parkinson's disease, Alzheimer disease etc..Impaired nerve fiber can be involved one or more types Nerve cell.
One of the severe challenge that protection after neurotrosis is faced with reparation always neuroscientists.By many years Effort, many researchs have confirmed that nervous system has plasticity, and not being showed only as the various stimulations in external boundary has strong generation It repays and adaptability, it is often more important that there is the ability itself repaired or rebuild after damage in structure and function.This process Realization not only need to start the certain gene regulation programs of nerve cell itself, but also need considerably complicated local environment and condition.
Currently, being only limited only to operative treatment for neural restoration, the mode of few effective oral medicines exists, state Inside have least a portion of Chinese medicine composition at present, have a certain curative effect to neural restoration, but big multicomponent effect is uncertain, effectively at Point also inaccurate, side effect is also without investigation.Therefore find that a kind of ingredient is bright and clear, the effective group for promoting neural restoration Object is closed, is this field thing very urgent at present.
Summary of the invention
It is an object of the invention to overcome the above-mentioned prior art, a kind of combination for promoting nervous system reparation is provided Object and the preparation method and application thereof.
In order to solve the above technical problems, invention uses technical solution as described below.It is a kind of to promote nervous system reparation Composition comprising following component:
Preferably, the composition for promoting nervous system reparation further includes the bulk pharmaceutical chemicals of 1-10 parts by weight, the raw material Medicine includes Radix Astragali, covers plate, anthocyanidin, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, acer truncatum buge oil, olive oil, zinc carbonate, aconiti preparata,radix, Huang One or more of company, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, the coptis, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Radix Angelicae Sinensis, Radix Glycyrrhizae.
Preferably, the bulk pharmaceutical chemicals include at least Radix Astragali, cover plate, anthocyanidin, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, acer truncatum Oil, olive oil, zinc carbonate, aconiti preparata,radix, the coptis, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, the coptis, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, when Return, ten kinds in Radix Glycyrrhizae.
Preferably, the composition for promoting nervous system reparation further includes the auxiliary material of 1-10 parts by weight, the accessory package Include Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, friendship Join one or more of sodium carboxymethylcellulose, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, lactose.
Preferably, the auxiliary material include at least Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose, Sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, gas phase Three kinds in silica, lactose.
Preferably, the nicotinamide adenine dinucleotide, ginsenoside PPD, ginseng saponin Rh 2 and Herba Epimedii secondary glycosides Weight ratio between member is 3-6:3-5:2-4:4-6.
Preferably, the neurotrophic factor is selected from NGF, BDNF, NT-3, NT-4/5.
A kind of preparation method for the composition promoting nervous system reparation, according to the combination of above-mentioned promotion nervous system reparation The each component and proportion of object are prepared and are uniformly mixed.
Preferably, the preparation method of the composition for promoting nervous system reparation further includes two nucleoside of nicotinamide adenine The preparation of acid；The preparation of the nicotinamide adenine dinucleotide includes: to extract slightly mentioning for nicotinamide-nucleotide adenylyltransferase Object or its pure enzyme；
The crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase；
It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and trinosin Nicotinamide adenine dinucleotide is prepared for substrate.
A kind of application for the composition promoting nervous system reparation, the composition of above-mentioned promotion nervous system reparation is used In neural restoration.
The beneficial effects of the present invention are:
The composition of the promotion nervous system reparation can play reparation to neuron and promote adjustment effect, and safe and non-toxic Side effect.The ingredient of different role principle is combined by the present invention, by the compatibility relationship of monarch, produces collaboration effect It answers, produces unexpected technical effect.
Detailed description of the invention
Fig. 1 is infarct volume figure.
Fig. 2 is rotary bar test result figure.
Fig. 3 is grip test effect figure.
Specific embodiment
To make those skilled in the art that the purposes, technical schemes and advantages of invention be more clearly understood, below Invention is further elaborated in conjunction with the accompanying drawings and embodiments.
Embodiment one
A kind of composition promoting nervous system reparation comprising following component:
Preferably, the neurotrophic factor is selected from NGF, BDNF, NT-3, NT-4/5.
Preferably, the composition for promoting nervous system reparation comprising following component:
Wherein, the nicotinamide adenine dinucleotide, ginsenoside PPD, ginseng saponin Rh 2 and Herba Epimedii secondary aglycon Between weight ratio be preferably 3-6:3-5:2-4:4-6, it is optimal be 4:4:3:5.Inventor is on the basis of conventional formulation, for the first time It proposes plus specific with nicotinamide adenine dinucleotide and Herba Epimedii secondary aglycon, ginsenoside PPD, ginseng saponin Rh 2 etc. The theory of effective component, and using the theory as guiding theory, pass through a large amount of pharmacological evaluations.Traditional Chinese and western medicine theory mutually echoes, and is added each Being introduced into for the specific auxiliary material of class can have facilitation effect, above several components to neural restoration by other medicinal materials in the side of significantly improving Synergistic function has occurred.In existing report, nicotinamide adenine dinucleotide, Herba Epimedii secondary aglycon, ginsenoside PPD, Rh2 are only used separately as raw material, not yet retrieve any combination that preparation is used in conjunction with four at present Object, the present invention have obtained the technical effect of 1+1+1+1 > 4 by allotment.
In some preferred embodiments, the composition of the promotion nervous system reparation further includes 1-10 parts by weight Bulk pharmaceutical chemicals, the bulk pharmaceutical chemicals include Radix Astragali, cover plate, anthocyanidin, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, acer truncatum buge oil, olive oil, carbon Sour zinc, aconiti preparata,radix, the coptis, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, the coptis, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Radix Angelicae Sinensis, one in Radix Glycyrrhizae Kind is several.It is preferred that the bulk pharmaceutical chemicals include at least Radix Astragali, cover plate, anthocyanidin, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, member Precious maple oil, olive oil, zinc carbonate, aconiti preparata,radix, the coptis, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, the coptis, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Ten kinds in Radix Angelicae Sinensis, Radix Glycyrrhizae.Specifically, the bulk pharmaceutical chemicals by Radix Astragali, cover plate, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, olive oil, system Monkshood, the coptis, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Radix Angelicae Sinensis, Radix Glycyrrhizae composition.
In some preferred embodiments, the composition of the promotion nervous system reparation further includes 1-10 parts by weight Auxiliary material, the auxiliary material include Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty Acid esters, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, in lactose One or more.It is preferred that the auxiliary material includes at least Nipagin complex esters, fumaric acid, phosphate, xylitol, crystallite Cellulose, sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, sulfuric acid Calcium, fumed silica, three kinds in lactose.Specifically, the auxiliary material is by Nipagin complex esters, fumaric acid, phosphate, xylose Alcohol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, fumed silica group At.
It acts synergistically between each substance of component of the present invention, by clearing heat and detoxicating, activating microcirculation and removing stasis medicinal keeps the blood vessel of whole body extensive Complex elasticity, by original blood supply insufficiency to normal slow process is tended to, the Gene regulation element and effective active in Chinese medicine material divide Son enters blood, and go directly diseased region, in steady adjustment process, based on nourishing liver and kidney, repairs the impaired organizer of human body Official gradually controls the pathogenesis of diabetes, adjusts nerve system of human body, promotes blood circulation, play coordination and complex treatment Function, fundamentally thorough reverting diabetes pathogenesis, makes body reach rehabilitation；Putrefaction-removing granulation-promoting, warming meridian, QI invigorating are living Blood, mitigates limb pain, and the infection of control sore face improves local microcirculation, enhances the two-way transhipment function of endothelial cell, improves week Perineural conduction of velocity promotes the healing of tissue repair and the surface of a wound.
Embodiment two
A kind of preparation method for the composition promoting nervous system reparation, promotes nervous system according to described in embodiment one The each component and proportion of the composition of reparation are prepared and are uniformly mixed.
In some preferred embodiments, the preparation method of the composition of the promotion nervous system reparation further includes cigarette The preparation of amide adenine-dinucleotide；The preparation of the nicotinamide adenine dinucleotide includes: to extract nicotinamide riboside gland The crude extract of glycosides acyltransferase or its pure enzyme；
The crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase；
It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and trinosin (ATP) nicotinamide adenine dinucleotide is prepared for substrate.
Specific step is as follows:
By the plasmid pRSET bmj transformed competence colibacillus bacterial cell of niacinamide-containing nucleosides adenylyl transferase gene E.coliHB101 is cultivated 24 hours at upper 37 DEG C of Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation is single Be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) in 30 DEG C culture 20-24 hours.Bacterium is collected by centrifugation Body, and be suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used.Centrifugation (10 DEG C, 17,800g, 10 minutes) simultaneously collect supernatant, as thick leach protein (or crude extract).The nicotinamide riboside gland of recombination Glycosides acyltransferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17,800g, 10 minutes) and is collected supernatant, i.e., For partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization
Nicotinamide-nucleotide adenylyltransferase thick leach protein or partially purified albumen are taken, with washing enzyme buffer liquid (0.02MTris HCl/0.001MEDTA, pH7.0 solution) is diluted to protein content 5-10mg/ml.Enzyme dilution is molten with PB Liquid (2.0mol/L potassium dihydrogen phosphate, pH7.5) mixes in equal volume, and (10 milligrams of epoxy type fixed enzyme vector LX 3000 is added Enzyme/gram carrier), it is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Sock filtration is used after the reaction was completed, with washing enzyme buffer Liquid cleans 56 times, obtains immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase
Preparation substrate solution: the trinosin (ATP) of nicotinamide nucleotide, 10mmol/L containing 5mmol/L, The MgCl of 100mmol/LTris hydrochloride buffer and final concentration of 10mmol/L2, adjust pH to 7.5.1 milliliter of substrate solution is taken, Then 0.05 gram of immobilization nicotinamide-nucleotide adenylyltransferase is added, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C, 17800g, 15 minutes) and collect supernatant.Nicotinamide adenine in the supernatant as obtained by high pressure liquid chromatography (HPLC) measurement The content of dinucleotides.As a result, the conversion ratio that nicotinamide nucleotide is converted into nicotinamide adenine dinucleotide is more than 80%.
Several specific preparation methods are provided below
Preparation method 1:
First dried supplementary material is crossed into 30-80 mesh respectively, keep distribution of particle sizes uniform, mobility is more preferable, former auxiliary Material keeps drying, and the raw material screened is then carried out proportion weighing, is warming up to after adding water that mixing is sufficiently stirred at 25-40 DEG C After 50 DEG C are stirred 1 hour, composition is obtained.
Preparation method 2:
First dried supplementary material is crossed into 60 meshes respectively, keep distribution of particle sizes uniform, mobility is more preferable, and supplementary material is protected Drying is held, the raw material screened is then subjected to proportion weighing, while relevant auxiliary materials are added, stirred evenly.The sample that will be mixed Product are pelletized in granulator, and are dried and then carry out whole grain.It is subsequently placed into tablet press machine, adjusts tablet press machine parameter, Tabletting is carried out, theoretical slice weight is 500mg, finally carries out film coating, inspection and packaging.
Preparation method 3:
(1) it prepares content: dried supplementary material being crossed into 60 meshes respectively first, supplementary material keeps drying, then will The raw material screened carries out proportion weighing, while relevant auxiliary materials are added, and uniformly.
(2) prepared by soft capsule body: now glycerol and water are added in glue pot, are then separately added into gelatin and relevant auxiliary materials, Flexible glue utricule is made in stirring, vacuum outgas.
(3) it prepares capsule: above-mentioned prepared content and flexible glue utricule being dried by pelleting, sizing, ball is washed, dries in the air Ball picks up ball and packaging and other steps, and soft capsule is made.
Preparation method 4:
S1: taking optional component to be broken into coarse granule, adds 5 times of 70% ethyl alcohol heating and refluxing extraction 2h of amount, filtration；The dregs of a decoction add 3 again 70% ethyl alcohol heating and refluxing extraction 1h of amount again, filtration, filtrate merge, and recycle ethyl alcohol and are simultaneously concentrated under reduced pressure into relative density at 60 DEG C 1.35~1.40 thick paste, it is spare；
The resulting product of step 1: being added the water of 7 times of amounts by S2, and heating and refluxing extraction volatile oil 4h divides the volatilization for taking layering Oil, it is spare；The dregs of a decoction and medical fluid coarse filtration, filtrate centrifuge separation, supernatant and the dregs of a decoction save backup respectively；
S3: the dregs of a decoction merge after the volatile oil for taking essential component to obtain with S2 step, add water to cook extract it is secondary, for the first time plus 18 times of amount water extract 2h, and second plus 12 times of amount water extract 1h, coarse filtration, filtrate centrifuge separation, the supernatant and S2 extracted twice What step obtained extracts the supernatant merging after volatile oil, is concentrated under reduced pressure into the thick paste of relative density 1.35~1.40 at 60 DEG C, It is spare；
S4: taking dextrin, superfine silica gel powder, mixes, is added to the water concentrate contracting thick paste that above-mentioned S1 step obtains and obtains with S3 step To alcohol extracting concentration thick paste in, stir, laying, be dried in vacuo, crush, dextrin is added, spray into S2 step and obtain Volatile oil is sieved, and mixes, and is packed into capsule.
Embodiment three
A kind of application for the composition promoting nervous system reparation, by promotion nervous system reparation described in embodiment one Composition is used for neural restoration.
Specific experimental group is provided below and is tested
1, preparation promotes the composition of nervous system reparation
Each component are as follows:
Wherein, neurotrophic factor is selected from BDNF；Bulk pharmaceutical chemicals by Radix Astragali, cover plate, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, olive Oil, aconiti preparata,radix, the coptis, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Radix Angelicae Sinensis, Radix Glycyrrhizae composition；Auxiliary material is by Buddhist nun Moor golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, crosslinking carboxylic Sodium carboxymethylcellulose pyce, fumed silica composition.Nicotinamide adenine dinucleotide is prepared using following methods:
By the plasmid pRSET bmj transformed competence colibacillus bacterial cell of niacinamide-containing nucleosides adenylyl transferase gene E.coliHB101 is cultivated 24 hours at upper 37 DEG C of Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation is single Be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) in 30 DEG C culture 20-24 hours.Bacterium is collected by centrifugation Body, and be suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used.Centrifugation (10 DEG C, 17,800g, 10 minutes) simultaneously collect supernatant, as thick leach protein (or crude extract).The nicotinamide riboside gland of recombination Glycosides acyltransferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17,800g, 10 minutes) and is collected supernatant, i.e., For partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization
Nicotinamide-nucleotide adenylyltransferase thick leach protein or partially purified albumen are taken, with washing enzyme buffer liquid (0.02MTris HCl/0.001MEDTA, pH7.0 solution) is diluted to protein content 5-10mg/ml.Enzyme dilution is molten with PB Liquid (2.0mol/L potassium dihydrogen phosphate, pH7.5) mixes in equal volume, and (10 milligrams of epoxy type fixed enzyme vector LX 3000 is added Enzyme/gram carrier), it is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Sock filtration is used after the reaction was completed, with washing enzyme buffer Liquid cleans 56 times, obtains immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase
Preparation substrate solution: the trinosin (ATP) of nicotinamide nucleotide, 10mmol/L containing 5mmol/L, The MgCl of 100mmol/LTris hydrochloride buffer and final concentration of 10mmol/L2, adjust pH to 7.5.1 milliliter of substrate solution is taken, Then 0.05 gram of immobilization nicotinamide-nucleotide adenylyltransferase is added, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C, 17800g, 15 minutes) and collect supernatant.Nicotinamide adenine in the supernatant as obtained by high pressure liquid chromatography (HPLC) measurement The content of dinucleotides.As a result, the conversion ratio that nicotinamide nucleotide is converted into nicotinamide adenine dinucleotide is more than 80%.
2, repairing nerve damage and the method for promotion functions post-equalization
Animal: this example meets U.S. national health office and announces its " experimental animal is looked after and guide for use " (NIH publication Number 85-23, is revised for 1996).This research uses 300 to 350 grams of weight of Male Long-Evans rats (National Laboratory Animal Breeding and research center).These animal feedings are in the room that a temperature (24 ± 1 DEG C) and humidity (55 ± 5%) are controlled Interior, light dark period is 12:12 hours.They can freely obtain food and drinking-water.
Surgical procedure: this technology is by method (Huang SS, Tsai SK, the Chih CL, Chiang of Huang et al. LY, Hsieh HM, Teng CM, Tsai MC；Neuroprotection of the six sulfobutyl group C60 to the rat for suffering from focal cerebral ischemia Effect.Free Radic.Biol.Med.2001；30:643-649) modified.In short, seasonal each making arrangements for surgery Male Long-Evans rats inhaled nitric oxide/oxygen/fluothane (69%: 30%: 1%) mixture and anaesthetized.Average of operation periods Between body temperature with heating cushion maintain 37 ± 0.5 DEG C, which is to make SERVO CONTROL with an anus temperature detector.In the tail portion outside of belly Artery is intubated, and is continued with StathamTM P23 XL transducer monitor heartbeat and mean arterial blood pressure (MABP) and is shown in On Gould RS-3400 physiology register (Gould, Cleveland, OH, USA).Use blood gas analyzer (GEM- 5300I.L.CO, USA) make blood sampling to test pH, PO in blood2And PCO2.Before unilateral MCA occlusion, period and thereafter It measures.
Block in manufacturing focal ischemia in the region MCA of right cortex.Two one are exposed with the incision of middle line forward neck portion As arteria carotis.The animal is laterally located, among the right eye angle and preceding auricle between point make incision of skin.Temporalis meat is retracted, and In cheekbone and the use of squamosal bone plotted point through the water-soluble night cooling of physiology salt awl (DremelTM Multipro+5395, Dremel com, USA) make small (diameter 3mm) skull excision.Using disecting microscope (OPMI-1, ZISS, Germany), Dura mater is opened with tapering tweezers, right MCA is bundled with 10-0 filament nylon knot.Then close two general arteria carotis with arteriole folder Plug one hour.After removing clip, it can visually restore blood flow into artery.
Experimental group: after FCI is injured, rat is distributed with random sequence to one of four processing groups (each n=6): (a) The composition of the oral promotion nervous system reparation being prepared；(b) prior art group: it is oral on the market it is common have repair Neurergic composition；(c) control group: oral normal saline；(d) camouflage group: animal is by surgery hand as hereinbefore Art program, but bundled without MCA.
Infarct volume analysis: after focal cerebral ischemia one hour and four week of Reperfu- sion, by rat anesthesia and with quick The mode of beheading is killed.Brain, the anatomical structure of visual detection MCA and bleeding or infection sign are removed, it is soaked in cold physiology Ten minutes in saline solution, and use brain matrix slicer (JACOBOWITZTM Systems, Zivic-Miller Laboratories INC, Allison Park, USA) it is cut into standard head slice (each 2mm is thick).Slice is placed in living body dye Material 2,3,5- triphenyltetrazol chloride (TTC, 2%；Sigma, USA) in, through 30 minutes in dark at 37 DEG C, then It is placed in 10% formalin, at room temperature overnight.It is dyed via TTC, right brain hemisphere and left brain hemisphere and blocking tissue Clear-cut visible (Chen ST Hsu CY, Hogan EL, Maricq H, Balentine JD；Focal ischemic stroke in The model of rat: reproducible popularity cortical infarct.Stroke.1986；17:738-743).It is (color using an image dissector Color image scanner, EPSONTM GT-9000) the grade profiles are depicted in the rear surface of each slice, which connects Knot is to one in image analysis system (AIS software, the Imaging of execution on personal computer (AMDTM K6-23D400) Research INC, Canada).The measurement of infarct size is the area that the area of opposite side is subtracted to harmless side brain hemisphere.Stalk The calculating of cock body product is to be sliced the summation of infarct size multiplied by slice thickness for every.Surgeon and image dissector operator The processing that each animal is received is not known.
Reproducible cerebral infarction has been obtained in the right MCA occlusion areas of prior art group and embodiment group and control group. The 4th week end after FCI injury, with control group (124.0 ± 20.0mm3) compare, the infarct volume of embodiment group has significant drop Low (69.1 ± 12.4mm3, P < 0.05), but prior art group is then without (108.0 ± 12.1mm3) (Fig. 1).
The result is pointed out, in the brain tissue of infraction after FCI injury, takes orally the promotion nervous system reparation being prepared Composition can significantly reduce 44.3% and 36% total infarct volume.
Behavior test: behavior measure is turned first, second, third and when 4th week end after focal FCI injury Dynamic stick test and grip test.
Rotary bar test:
Use movement defect (Hamm RJ, Pike BR, O ' of the acceleration rotary bar assessment rat after ischemic damage Dell DM, Lyeth BG, Jenkins LW；Rotary bar test: its movement defect side after assessment traumatic cerebral injury is assessed The effect in face.J.Neurotrauma.1994；11:187-196).Rat is placed at the spoke of the rotary bar in accelerating, and is surveyed Measure the time that the animal is maintained on rotary bar.Speed is to be slowly increased to 40rev/ by 4rev/min in five-minute period min.The time that each animal falls spoke is to note down in seconds.Each animal receives long run test three times.
The rotary bar test result of each group is shown in Fig. 2.Before preparing in the preoperative, four groups of animal stays in the rotary bar Shangdi time Have no significant difference.After FCI injury when the first weekend, rat stays in the average period on rotary bar in control group, the prior art Group and embodiment group are respectively 55.0%, 50.3% and 92.2% (P < 0.05vs. control group and only GDNF group) of base value, But FCI injury after 4th week end when be then base value 75.3%, 67.3% and 106.6% (P < 0.05vs. control group and only GDNF group).As the result is shown after FCI is injured, it is significant that the rat of control group and only GDNF group stays in the time on rotary bar for this The shorter than animal of GDNF- Fibrin Glue group.This result is pointed out can in Fibrin Glue of the brain injuries region overlay containing GDNF Improve the sense of equilibrium of rat and harmony after FCI is injured.
Grip test:
The test of this grip is by method (Bertelli JA, the Mira JC of Bertelli et al.；Grip test: one Simple behavioral approach of the kind for objective quantification assessment rat peripheral nerve regeneration.J. Neurosci.Methods.1995；59: 151-155) modify.To assess grip strength, a wire stick is connected to an ordinary electronic scale.Two front foots are equal Prediction examination, foot is tied before temporarily being tested with adhesive tape, and is intended to the front foot tested and is then kept freely.Mouse is picked up by tail portion, It is enabled to grasp the stick until loosing one's grip with cumulative fastness, score its grip.
Four groups of grip test effect is shown in Fig. 3.In four groups, the average grip of the left front foot of rat is closed in right MCA Significant difference is had no before plug, and the average grip of Rat Right front foot is before right MCA occlusion and first, second, third after occlusion And without significant difference when 4th week end.
After FCI injury when the first weekend, the average value of grip is respectively in control group, prior art group and embodiment group 78.7%, 71.7% and 101.2% (P < 0.05vs. control group and only GDNF group) of base value, but 4th week after FCI injury It is then 89.6%, 97.6% and 120.7% (P < 0.05vs. control group) of base value when last.
It is related with the improvement of rat grip strength after FCI is injured that this takes orally composition described in embodiment as the result is shown.
Statistics: data are indicated with average value ± average stdev (S.E.M.).Rat infarct volume and behavioral deficiency The statistical analysis of score difference is carried out with the double tail t tests and the two-way analysis of variable (ANOVA) of merging data of non-matching, In order to the difference between assessment control group and processing group.The numerical value of P < 0.05, which can be considered, statistically has conspicuousness.
3, clinical test
Case 1: section, 40 years old, female.: there is left side cheek and left bicker pain repeatedly in main suit, is in cut sample severe pain, often Secondary duration etc., about a few minutes to dozens of minutes, idol to a few houres repeated multiple times can break out in one day.It checks: complexion White, chronic face dolorosa, cranial nerve no abnormality seen, facial perception is accessible, causes the sample severe pain that shocks by electricity when touching left side cheek.It examines It is disconnected: trigeminal neuralgia.After taking 2 courses for the treatment of of tablet obtained by the embodiment of the present invention, paroxysmal pain number is obviously less, pain Pain degree also mitigates significantly, continues to take 1 course for the treatment of, and pain substantially no longer occurs, and it is normal to tap cheek reaction.Follow-up 1 year More, pain seldom occurs.
Case 2: Mr. Wang, 53 years old, male.Main suit: right side face shocks by electricity sample pain 6 years, and pain position is mainly on the right side of place between the eyebrows. There is the swollen sense of right side bicker acid every a few days within nearly 1 year, it is stimulated, cause place between the eyebrows-right face-right side bicker region electric shock sample Pain is fed, pain can also be induced by brushing teeth.It is checked through hospital, is diagnosed as primary trigeminal neuralgia.Take the embodiment of the present invention After obtained 1 course for the treatment of of tablet, attack times are reduced, and symptom mitigates, after continuing two courses for the treatment of of medication, significant effect, and pain Disease disappears, and spirit increases substantially more habitually in the past, and in follow-up half a year, patient is not recurred.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie In the case where without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter From the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended power Benefit requires rather than above description limits, it is intended that all by what is fallen within the meaning and scope of the equivalent elements of the claims Variation is included within the present invention.
The above is only a preferred embodiment of the present invention, protection scope of the present invention is not limited merely to above-mentioned implementation Example, all technical solutions belonged under thinking of the present invention all belong to the scope of protection of the present invention.It should be pointed out that for the art Those of ordinary skill for, several improvements and modifications without departing from the principles of the present invention, these improvements and modifications It should be regarded as protection scope of the present invention.

Claims (10)

1. a kind of composition for promoting nervous system reparation, it is characterised in that: it includes following component:
2. promoting the composition of nervous system reparation as described in claim 1, it is characterised in that: further include 1-10 parts by weight Bulk pharmaceutical chemicals, the bulk pharmaceutical chemicals include Radix Astragali, cover plate, anthocyanidin, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, acer truncatum buge oil, olive oil, carbon Sour zinc, aconiti preparata,radix, the coptis, Asian puccoon, Cortex Phellodendri, myrrh, dragon's blood, the coptis, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Radix Angelicae Sinensis, one in Radix Glycyrrhizae Kind is several.
3. promoting the composition of nervous system reparation as claimed in claim 2, it is characterised in that: the bulk pharmaceutical chemicals include at least Radix Astragali covers plate, anthocyanidin, Bulbilus boussingaultiae pseudobaselloidis, rhizoma zingiberis, astaxanthin, acer truncatum buge oil, olive oil, zinc carbonate, aconiti preparata,radix, the coptis, purple Grass, Cortex Phellodendri, myrrh, dragon's blood, the coptis, Cortex Phellodendri, smallflower milkwort herb with root, rhizoma corydalis, Radix Angelicae Sinensis, ten kinds in Radix Glycyrrhizae.
4. promoting the composition of nervous system reparation as described in claim 1, it is characterised in that: further include 1-10 parts by weight Auxiliary material, the auxiliary material include Nipagin complex esters, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty Acid esters, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, in lactose One or more.
5. promoting the composition of nervous system reparation as claimed in claim 4, it is characterised in that: the auxiliary material includes at least Buddhist nun Moor golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, crosslinking carboxylic Sodium carboxymethylcellulose pyce, magnesium hydroxide, pregelatinated shallow lake, calcium sulfate, fumed silica, three kinds in lactose.
6. promoting the composition of nervous system reparation as described in claim 1, it is characterised in that: the nicotinamide adenine two Weight ratio between nucleotide, ginsenoside PPD, ginseng saponin Rh 2 and Herba Epimedii secondary aglycon is 3-6:3-5:2-4:4-6.
7. the composition of promotion nervous system reparation as described in claim any one of 1-6, it is characterised in that: the nerve Trophic factors is selected from NGF, BDNF, NT-3, NT-4/5.
8. a kind of preparation method for the composition for promoting nervous system reparation, it is characterised in that: promote according to described in claim 1 Each component and proportion into the composition of nervous system reparation are prepared and are uniformly mixed.
9. promoting the preparation method of the composition of nervous system reparation as claimed in claim 8, it is characterised in that: further include cigarette The preparation of amide adenine-dinucleotide；
The preparation of the nicotinamide adenine dinucleotide include: extract nicotinamide-nucleotide adenylyltransferase crude extract or its Pure enzyme；
The crude extract or its pure enzyme of immobilization recombination nicotinamide-nucleotide adenylyltransferase；
It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, using nicotinamide nucleotide and trinosin the bottom of as Object prepares nicotinamide adenine dinucleotide.
10. a kind of application for the composition for promoting nervous system reparation, it is characterised in that: mind will be promoted described in claim 1 Composition through system reparation is used for neural restoration.
CN201811000872.2A 2018-08-30 2018-08-30 Promote the composition and the preparation method and application thereof of nervous system reparation Withdrawn CN109350734A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811000872.2A CN109350734A (en) 2018-08-30 2018-08-30 Promote the composition and the preparation method and application thereof of nervous system reparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811000872.2A CN109350734A (en) 2018-08-30 2018-08-30 Promote the composition and the preparation method and application thereof of nervous system reparation

Publications (1)

Publication Number Publication Date
CN109350734A true CN109350734A (en) 2019-02-19

Family

ID=65350166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811000872.2A Withdrawn CN109350734A (en) 2018-08-30 2018-08-30 Promote the composition and the preparation method and application thereof of nervous system reparation

Country Status (1)

Country Link
CN (1) CN109350734A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037864A (en) * 2010-06-16 2013-04-10 安比拉神经疗法公司 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037864A (en) * 2010-06-16 2013-04-10 安比拉神经疗法公司 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
张姗姗等: "NADH和NADPH代谢和功能的研究进展", 《第二军医大学学报》 *
曾令荣等: "淫羊藿次苷Ⅱ下调APP/PS1转基因小鼠海马APP、Aβ1-42、RAGE蛋白水平并抑制炎症反应", 《遵义医学院学报》 *
李东薇等: "人参防治帕金森病的研究进展", 《神经药理学报》 *
毕祥云等: "阿尔茨海默病相关治疗的研究进展", 《中华保健医学杂志》 *
燕之屋: "诺贝尔医学奖:发现燕窝酸的补脑因子", 《领导文萃》 *
王苏华等: "S-腺苷蛋氨酸的神经保护作用的研究进展", 《毒理学杂志》 *
罗孝华: "枯草杆菌二联活菌颗粒与熊去氧胆酸胶囊联合对新生儿黄疸指数及行为神经发育的影响", 《中国当代医药》 *
马敏等: "硫酸软骨素药理学活性研究进展", 《食品与药品》 *

Similar Documents

Publication Publication Date Title
CN109125338A (en) A kind of composition and the preparation method and application thereof promoting nervous system reparation
WO2002060474A2 (en) Mixtures of mushroom enzymes and the use thereof for treating maldigestion
CN102614499B (en) Yak skin collagen compound traditional Tibetan medicine with anti-fatigue effect and preparation process thereof
CN113398144B (en) Application of nucleotide mixture in preparation of preparation for preventing or relieving sarcopenia of old people
CN106667915B (en) It is a kind of for treating the scutelloside aluminium dry suspensoid agent of grice diarrhoea
CN108743621A (en) The bear gall powder and preparation method of ice crystal state
CN106306533A (en) Traditional Chinese medicine feed for preventing and treating infectious bronchitis and preparation method thereof
CN103493983B (en) Feed additive for improving fur quality of fur-bearing animal and manufacturing method thereof
CN101152239A (en) Technique of preparing drone pupa freeze-dried powder medicinal granules and capsule
CN102091166B (en) Compound preparation for promoting neuromuscular regeneration and preparation method thereof
CN109350734A (en) Promote the composition and the preparation method and application thereof of nervous system reparation
DE60311595T2 (en) COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL COMPLAINTS
CN108651993A (en) A kind of male health-care composition, preparation and the preparation method and application thereof
CN110367367A (en) A kind of pressed candy and preparation method thereof making one deep sleep
CN104256618B (en) A kind of hypoglycemic food, health products or pharmaceutical composition
CN1258538A (en) Health food made of silkworm for treating diabetes and hyperlipemia and its production process
DE602004009199T2 (en) EFFECTS OF SPORODERM-BROKEN GERMINATION-ACTIVATED GANODERMA SPORTS ON THE TREATMENT OF BACKBONE INJURIES AND THE PROLIFERATION AND / OR DIFFERENTIATION OF NEURAL STEM CELLS IN INFRINGED BACKMARK
CN106038720A (en) Type-II diabetes preparation and preparation method thereof
CN108187013A (en) Wen Tongshu network compositions and preparation method and application
WO2005115423A1 (en) Using organic and/or inorganic potassium and its salts to treat autoimmune and other health disorders and methods of administering the same
CN109350652A (en) The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof
EP2842550B1 (en) Compositions comprising sponge collagen with a defined in vivo release profile, especially in the colon, their preparation and use
JP4293294B2 (en) Dementia remedy
CN108721607A (en) A kind of collagen-rich anti-senility oral liquid and preparation method thereof
CN107335052A (en) For treating the formulation product of diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190219